Next Bi-Annual Meeting:

February 5-7, 2025

Home
About
About POETIC
Research Development and Management Center (RDMC)
Scientific Advisory Board
- Scientific Advisory Board
Programs
Innovative Programs
Clinical Trials
Pre-Clinical Programs
Genetic Variation Across Single Cells
Metastasis and Exosome Developmental Laboratory
The Preclinical and Drug Discovery Laboratory
- Clinical Trials
- Pre-Clinical Programs
Members
POETIC Member Institutions
Alberta Children's Hospital
Alberta, Canada

Arkansas Children's Hospital
Little Rock, AR

Arnold Palmer Hospital for Children
Orlando, FL

City of Hope Comprehensive Cancer Center
Duarte, CA

Huntsman Cancer Institute
Salt Lake City, UT

Lucile Packard Children’s Hospital at Stanford
Palo Alto, CA

MD Anderson Cancer Institute
Houston, Texas

Memorial Sloan-Kettering Cancer Center
New York, NY

Penn State Health Children’s Hospital
Hershey, PA

Phoenix Children's Hospital
Phoenix, AZ

UT Health San Antonio
San Antonio, TX

University of Wisconsin Carbone Comprehensive Cancer Center
Madison, WI
Bi-Annual Meeting
Benefactors
News
Contact

Idasanutlin in combination with either chemotherapy or Venetoclax in the treatment of pediatric and young patients with relapsed/refractory acute leukemias or solid tumors

Q: Idasanutlin in combination with either chemotherapy or Venetoclax in the treatment of pediatric and young patients with relapsed/refractory acute leukemias or solid tumors

Sponsor: Genentech Protocol: GO40871 Estimated accrual years: 5 years (in 3 phases) [fusion_button link="https://clinicaltrials.gov/study/NCT04029688" title="" target="_blank" link_attributes="" alignment_medium="" alignment_small="" alignment="left" modal="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" sticky_display="normal,sticky" class="" id="" color="default" button_gradient_top_color_hover="" hue="" saturation="" lightness="" alpha="" button_gradient_top_color="" button_gradient_bottom_color_hover="" button_gradient_bottom_color="" gradient_start_position="" gradient_end_position="" gradient_type="" radial_direction="" linear_angle="180" accent_hover_color="" accent_color="" type="" bevel_color="" bevel_color_hover="" border_top="" border_right="" border_bottom="" border_left="" border_radius_top_left="" border_radius_top_right="" border_radius_bottom_right="" border_radius_bottom_left="" border_hover_color="" border_color="" size="large" padding_top="" padding_right="" padding_bottom="" padding_left="" fusion_font_family_button_font="" fusion_font_variant_button_font="" font_size="" line_height="" letter_spacing="" text_transform="" stretch="default" margin_top="10px" margin_right="" margin_bottom="50px" margin_left="" icon="fa-long-arrow-alt-right fas" icon_position="right" icon_divider="no" hover_transition="none" animation_type="" animation_direction="left" animation_color="" animation_speed="0.3" animation_delay="0" animation_offset=""] Read more about this trial at ClinicalTrials.gov[/fusion_button]

Sponsor: Genentech

Protocol: GO40871

Estimated accrual years: 5 years (in 3 phases)

By poetic_admin|2024-05-14T01:38:37+00:00November 15, 2023|0 Comments

About the Author: poetic_admin

Contact

Phone: (650) 736-0269

Email: poeticrdmc@stanford.edu

Donate to The POETIC Foundation

Sign up for Our Quarterly POETIC Newsletter

Receive updates on POETIC’s recent activities.

Last updated: July 2024

Research Development and Management Center (RDMC)

Scientific Advisory Board

Clinical Trials

Pre-Clinical Programs

Genetic Variation Across Single Cells

Metastasis and Exosome Developmental Laboratory

The Preclinical and Drug Discovery Laboratory

Alberta Children's Hospital

Arkansas Children's Hospital

Arnold Palmer Hospital for Children

City of Hope Comprehensive Cancer Center

Huntsman Cancer Institute

Lucile Packard Children’s Hospital at Stanford

MD Anderson Cancer Institute

Memorial Sloan-Kettering Cancer Center

Penn State Health Children’s Hospital

Phoenix Children's Hospital

UT Health San Antonio

University of Wisconsin Carbone Comprehensive Cancer Center

Idasanutlin in combination with either chemotherapy or Venetoclax in the treatment of pediatric and young patients with relapsed/refractory acute leukemias or solid tumors

About the Author: poetic_admin

Leave A Comment Cancel reply

Contact

Sign up for Our Quarterly POETIC Newsletter

You are now leaving poeticphase1.org

Research Development and Management Center (RDMC)

Scientific Advisory Board

Clinical Trials

Pre-Clinical Programs

Genetic Variation Across Single Cells

Metastasis and Exosome Developmental Laboratory

The Preclinical and Drug Discovery Laboratory

Alberta Children's Hospital

Arkansas Children's Hospital

Arnold Palmer Hospital for Children

City of Hope Comprehensive Cancer Center

Huntsman Cancer Institute

Lucile Packard Children’s Hospital at Stanford

MD Anderson Cancer Institute

Memorial Sloan-Kettering Cancer Center

Penn State Health Children’s Hospital

Phoenix Children's Hospital

UT Health San Antonio

University of Wisconsin Carbone Comprehensive Cancer Center

Idasanutlin in combination with either chemotherapy or Venetoclax in the treatment of pediatric and young patients with relapsed/refractory acute leukemias or solid tumors

Share This Story, Choose Your Platform!

About the Author: poetic_admin

Leave A Comment Cancel reply

Contact

Sign up for Our Quarterly POETIC Newsletter

You are now leaving poeticphase1.org